AndzonBio2 Expands Neuroinflammation Pipeline Through Collaboration with Inserm and University of Lille, and receives non-dilutive financial support for its new program
Paris, 22nd September 2026 – AndzonBio2, a biotechnology company developing next-generation therapeutics for neuroinflammatory and neurodegenerative diseases, today announced the execution of agreements with Inserm Transfert and the launch of a strategic research…
AndzonBio2, the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise Announce a Collaboration to Develop First-in-Class Therapeutics for Neuroinflammation
Paris, France and Cambridge, UK, May 13, 2026 – AndzonBio2 today announced the signature of agreements with the ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance…
AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership Appointment.
Paris, February 3, 2026 – AndzonBio2, a biotechnology company focused on developing innovative therapeutic programs in neuroinflammation, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading experts in neuroscience,…
AndzonBio2 emerges from stealth mode and announces initial €3M seed fundingto advance breakthrough treatments for neurological disorders.
Paris, France, October 23, 2025 – AndzonBio2 emerges from stealth mode and announces a €3M ($3.5M) seed funding from AdBio Partners, a venture capital company builder fund specialized in early-stage investments in life…